Drug Profile

Research programme: transdermal hydrogel patch therapeutics - Adynxx

Alternative Names: Alliqua Hydrogel technology; Lidocaine hydrogel patch; Transdermal pain patch - Adynxx

Latest Information Update: 14 May 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alliqua
Developer Adynxx
Class Acetanilides; Small molecules
Mechanism of Action Sodium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Postherpetic neuralgia

Most Recent Events

06 May 2019 Alliqua Biomedical has merged with Adynxx to form Adynxx
20 Apr 2017 Discontinued - Preclinical for Postherpetic neuralgia in USA (Transdermal)
24 Oct 2013 Final pharmacokinetics and adverse events data from a preclinical trial in Postherpetic neuralgia released by Alliqua

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com